Page 12 - Lupin

Stocks to watch: Glenmark Pharma, NTPC, V-Guard Inds, Lupin, YES Bank, NDTV

Stocks to watch today: Jaiprakash Associates has called a board meeting on Monday, December 12, to mull over sale of their Nilgrie cement unit in Madhya Pradesh

Lupin to enter cardio-vascular therapeutics space in 10 cities by Feb

Move will mark firm's digital healthcare foray 18 months after announcement; firm also plans to enter mental and respiratory illness segments, cover 28-30 cities by CY 2023-end

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

Stocks to Watch: HCL Tech, Lupin, Fusion Micro Fin, Five-Star, NBCC, PNB

Stocks to Watch Today: Newly listed Fusion Micro Finance and Five-Star Business are likely to be in focus on the back of strong Q2 performance reported by the companies.

Stocks to Watch: PNB, Tube Investments, Indian Oil, Laurus Labs, SBI, Lupin

Stocks to Watch: Punjab National Bank (PNB) on Thursday said it received the government's approval to divest its entire stake (15.22 per cent) in UTI Asset Management Company

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Stocks to Watch: Reliance, Nykaa, NDTV, Kaynes Technology, PFC, JK Paper

Stocks to Watch: Kaynes Technology will make its debut today. The issue price is fixed at Rs 587 per share

Mehul Kothari expects Ashok Leyland to break its all-time high; Check why

According to the technical analyst from Anand Rathi, Ashok Leyland can potentially break its all-time high at Rs 169.45, while he is also bullish on Lupin.

Lupin posts net profit of Rs 130 cr in Q2, revenue rises to Rs 4,145 cr

Drug maker Lupin on Wednesday said its consolidated net profit stood at Rs 130 crore for the second quarter ended September 30, 2022. The Mumbai-based company had reported a net loss of Rs 2,098 crore in the July-September period of the previous fiscal. Total revenue from operations rose to Rs 4,145 crore for the period under review as compared to Rs 4,091 crore in the year-ago period, Lupin Ltd said in a regulatory filing. The company said it paid Rs 1,878 crore towards litigation and settlement related expenses last year with respect to antitrust class action filed in the US in connection with the drug Glumetza. "We have performed in line with our expectations during the quarter, and are on the path of steady growth in sales and profitability. Our sales growth sequentially was robust as our US business bounced back. "Our India business delivered continued growth in line with the market, excluding the impact of loss of exclusivity and certain sales in the diabetes and cardiovascu

Drug firm Lupin gets USFDA nod to market generic antibiotic medicine in US

Drug firm Lupin on Tuesday said it has received approval from the US health regulator to market Doxycycline Capsules used to treat bacterial infections in the American market. The drug firm has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Doxycycline Capsules, 40 mg, a generic equivalent of Galderma Laboratories' Oracea capsules, Lupin Ltd said in a statement. As per IQVIA MAT September 2022 data, Doxycycline capsules had estimated annual sales of USD 215 million in the US market.

Lupin gets US drug regulator's nod for generic oral contraceptive pill

Drug maker Lupin on Friday said it has received approval from the US health regulator to market Drospirenone tablets, used to prevent pregnancy, in the American market. The company has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Drospirenone Tablets in 4 mg strength, the Mumbai-based drug maker said in a statement. The company's product is the generic equivalent of Exeltis USA Inc's Slynd tablets, it added. As per IQVIA MAT September 2022 data, Drospirenone tablets had estimated annual sales of USD 141 million in the US market.

Sensex recoups 350pts from day's low, ends flat; Nifty holds 18K; SBI up 2%

CLOSING BELL: IT, Power stocks logged significant losses, even as select financial stocks gained.

USFDA issues warning letter to Lupin for Maharashtra-based API plant

The US health regulator has pulled up drug maker Lupin for manufacturing lapses, including failure to establish adequate written procedures for cleaning equipment, at its Maharashtra-based plant. In a warning letter, the US Food and Drug Administration (USFDA) has pointed out various lapses at the Tarapur (Thane) plant which produces active pharmaceutical ingredients (API). "This warning letter summarises significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API)," the US health regulator said. It further said: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API is adulterated..." The USFDA inspected the manufacturing facility from March 22 to April 4, 2022. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. In the warning letter the health regulator pointed out the company

Lupin inks pact to acquire two inhalation brands from Sunovion for $75 mn

Drug maker Lupin on Thursday said it will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for USD 75 million (around Rs 622 crore). The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol. The Mumbai-based firm expects the transaction to be accretive to earnings in the first year. The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA), indicated for the treatment or prevention of bronchospasm in adults, ...

Lupin ties up with global agencies to support tuberculosis treatment

Drug firm Lupin on Friday said it has tied up with Unitaid, The Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis prevention treatment initiative to be rolled out to 138 countries. As per the agreement, the Mumbai-based firm will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price in various regions, including many low-and middle-income countries with a large burden of tuberculosis (TB). "We are committed to enhancing the global access to affordable and high-quality drugs and APIs for the treatment of tuberculosis... "Through this, we will further reinforce our long legacy to provide shorter, more patient-friendly treatment options to prevent TB," Lupin Managing Director Nilesh Gupta said in a statement. Lupin is a leading player in the cardiovascular, anti-diabetic, and respiratory segments.

Lupin gets USFDA nod to market generic HIV drug Darunavir tablets

Drug firm Lupin on Tuesday said it has received an approval from the US health regulator to market Darunavir Tablets, used to treat Human Immunodeficiency Virus (HIV) infection, in the American market. The Mumbai-based company said it is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity. Lupin will also potentially have shared 180-day exclusivity on the 600 mg tablets, it added. The company has received the approval from the US Food and Drug Administration (USFDA) for the medication in strengths of 600 mg and 800 mg, Lupin said. The drug firm's product is a generic equivalent of Janssen Products' Prezista Tablets. As per MAT June 2022 data, Darunavir tablets (600 mg and 800 mg) had estimated annual sales of USD 343 million in the US. Lupin shares were trading 2.17 per cent up at Rs 738.30 apiece on the BSE.

Stocks to Watch: Hero Moto, Adani Enterprises, Zydus Life, Vodafone Idea

Stocks to Watch today: Hero MotoCorp said it will invest USD 60 million (about Rs 490 crore) in US-based Zero Motorcycles to jointly develop electric motorcycles

Lupin gets warning letter from USFDA for Tarapur API plant in Maharashtra

Drug firm Lupin on Thursday said it has received a warning letter from the US health regulator for its Tarapur-based manufacturing facility in Maharashtra. The US Food and Drug Administration (USFDA) inspected the site from March 22, 2022 to April 4, 2022. The company manufactures both fermentation-based and synthetic APIs (active pharmaceutical ingredients) at the plant. "The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility," the Mumbai-based company said in a regulatory filing. The drug firm is committed to addressing the concerns raised by the USFDA and will work with the agency to resolve the issues at the earliest, it added. Lupin did not share details about the issues flagged by the US health regulator. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. The letter identifies the violation, such as

Lupin receives approval from US FDA for Sildenafil for Oral Suspension

The company has launched the tablets in strengths of 5 mg, 20 mg and 40 mg after having received an approval from the United States Food and Drug Administration earlier, Lupin Ltd said in a statement

Lupin dips 3% as US FDA issues warning letter for Tarapur facility

Lupin said it does not believe the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility